Furthermore, in an experimental setting of non-alcoholic steatohepatitis in rats, adalimumab has been declared to significantly decrease the serum TNF–α and IL-6 levels33 . This evidence concerns the gene IL6 and metabolic dysfunction-associated steatohepatitis.